An overview of obesity in children with psychiatric disorders taking atypical antipsychotics

Harvard Review of Psychiatry

Volumn 16, Issue 2, 2008, Pages 69-79

  Shin, Lauren ^a,b   Bregman, Hallie ^a   Frazier, Jean ^a   Noyes, Nancy ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b CAMBRIDGE HEALTH ALLIANCE   (United States)

Author keywords

Adolescents; Atypical antipsychotic; Children; Mental illness; Metformin; Obesity; Overweight; Psychiatric illness; Treatment; Weight gain

Indexed keywords

AMANTADINE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZATROPINE; BENZODIAZEPINE; BETAHISTINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOMIPRAMINE; CLOZAPINE; GUANFACINE; METFORMIN; MODAFINIL; OLANZAPINE; PLACEBO; PROPRANOLOL; QUETIAPINE; RANITIDINE; RECOMBINANT CILIARY NEUROTROPHIC FACTOR; RISPERIDONE; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TOPIRAMATE; TRIHEXYPHENIDYL; VALPROIC ACID;

BEHAVIOR THERAPY; CHILDHOOD DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; CYANOCOBALAMIN DEFICIENCY; DIABETIC KETOACIDOSIS; DIET THERAPY; DISEASE PREDISPOSITION; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG INDUCED DISEASE; EXERCISE; FAMILY; FLATULENCE; FOLIC ACID DEFICIENCY; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERTENSION; INTERVENTION STUDY; KIDNEY FAILURE; LACTIC ACIDOSIS; LOOSE FECES; MANIA; MENTAL DISEASE; NUTRITIONAL SUPPORT; OBESITY; PATIENT EDUCATION; PRIORITY JOURNAL; REVIEW; SEDATION; SIDE EFFECT; STEATORRHEA; TACHYCARDIA; UNSPECIFIED SIDE EFFECT; WEIGHT CONTROL; WEIGHT GAIN;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; APPETITE DEPRESSANTS; CHILD; CHILD, PRESCHOOL; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; DIET, REDUCING; EXERCISE; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MENTAL DISORDERS; METFORMIN; OBESITY; PATIENT ADMISSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 42249099771     PISSN: 10673229     EISSN: 14657309     Source Type: Journal    
DOI: 10.1080/10673220802073915     Document Type: Review

References (113)

1. Casazza K, Ciccazzo M. Improving the dietary patterns of adolescents using a computer-based approach. J Sch Health 2006;76:43-6.
2. Institute of Medicine. Childhood obesity in the United States: facts and figures. 2005. http://www.iom.edu/Object.File/Master/ 22/606/ FINALfactsandfigures2.pdf
3. Mack R, Skurnick B, Sterling-Jean Y, Pedra-Nobre M, Bigg D. Fasting insulin levels as a masure of insulin resistance in American blacks. J Appl Res 2004;4:90-4.
4. Rao G. Insulin resistance syndrome. Am Fam Physician 2001;63:1-7.
5. Kanai H, Matsuzawa Y, Tokunaga K, et al. Hypertension in obese children: fasting serum insulin levels are closely correlated with blood pressure. Int J Obes 1990;14:1047-56.
6. Sjoberg R, Nilsson K, Leppert JJ. Obesity, shame, and depression in school-aged children: a population-based study. Pediatrics 2005;116:389-92.
7. Vila G, Zipper E, Dabbas M, et al. Mental disorders in obese children and adolescents. Psychosom Med 2004;66:387-94.
8. Janssen I, Craig W, Boyce W, Pickett W. Associations between overweight and obesity with bullying behaviors in school-aged children. Pediatrics 2004;113:1187-94.
9. Allison D, Fontaine K, Heo M, et al. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry 1999;60:215-20.
10. Burkart J, Fox R, Rotatori A. Obesity of mentally retarded individuals: prevalence, characteristics, and intervention. Am J Ment Defic 1985;90:303-12.
11. Jones B, Basson B, Walker D, Crawford A, Kinon B. Weight change and atypical antipsychotic treatment in patients with schizophrenia. J Clin Psychiatry 2001;62:41-4.
12. Weiden P, McEvoy J. Managing health risks in psychiatric patients: practical clinical interventions. Clin Psychiatry News 2006;supp:3-11.
13. Tandon R, Jibson. Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology 2003;29:9-26.
14. Jin H, Meyer J, Jeste D. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry 2002;14:59-64.
15. Correll C, Frederickson A, Kane J, Manu, P. Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res 2007;89:91-100.
16. Allison D, Mentore J, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-96.
17. Correll C, Penzner J, Parikh U, et al. Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child Adolesc Psychiatr Clin N Am 2006;15:177-206.
18. Masi G, Mucci M, Millepiedi S. Clozapine in adolescent inpatients with acute mania. J Child Adolesc Psychopharmacol 2002;12:93-9.
19. Shaw P, Sporn A, Gogtay N, et al. Childhood-onset schizophrenia. Arch Gen Psychiatry 2006;63:721-30.
20. Frazier J, Biederman J, Tohen M, et al. A prospective openlabel treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol 2001;11:239-50.
21. Kumra S, Kranzler H, Gerbino-Rosen G, et al. Clozapine and "high dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. J Biopsychiatry 2008;63;524-9.
22. Sikich L, Hamer R, Bashford R, Sheitman B, Lieberman J. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology 2004;29:133-45.
23. Biederman J, Mick E, Hammerness P, et al. Open-label, 8 week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children. Biol Psychiatry 2005;56;589-94.
24. Tohen M, Kryzhanovskaya L, Carlson G, et al. Olanzapine vs. placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry 2007;164:1547-56.
25. Marchand W, Wirth L, Simon C. Quetiapine adjunctive and monotherapy for pediatric bipolar disorder: a retrospective chart review. J Child Adolesc Psychopharmacol 2004;4:405-11.
26. DelBello M, Kowatch R, Adler C, et al. A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. J Am Acad Child Adolesc Psychiatry 2006;45:305-13.
27. Biederman J, Mick E, Wozniak J, et al. An open-label trial of risperidone in children and adolescents with bipolar disorder. J. Child Adolesc Psychopharmacol 2005;15:311-7.
28. Correll C. Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials. J Am Acad Child Adolesc Psychiatry 2007;46:687-700.
29. Weiden P, Mackell J, McDonnell D. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res 2004;66:51-7.
30. O'Brien S, Holubkov R, Reis E. Identification, evaluation, and management of obesity in an academic primary care center. Pediatrics 2004;114:154-9.
31. Littrell K, Hilligoss N, Kirshner C, Petty R, Johnson C. The effects of an educational intervention on antipsychotic-induced weight gain. J Nurs Scholarsh 2003;35:237-41.
32. Evans S, Newton R, Higgins S. Nutritional intervention to prevent weight gain in patients commenced on olanzapine: a randomized controlled trial. Aus NZ J Psychiatry 2005;39:479-86.
33. Eliakim A, Friedland O, Kowen G, Wolach B, Nemet D. Parental obesity and higher pre-intervention BMI reduce the likelihood of a multidisciplinary childhood obesity program to succeed - a clinical observation. J Pediatr Endocrinol Metab 2004;17:1055-61.
34. Diamond G, Siqueland I. Current status of family intervention science. Child Adolesc Psychiatr Clin N Am 2001;10:641-61.
35. Jiang J, Xia X, Greiner T, Lian G, Rosenqvist U. A two-year family-based behaviour treatment for obese children. Arch Dis Child 2005;90:1235-8.
36. Vreeland B, Minsky B, Menza M, Radler D, Roemheld-Hamm B, Stern R. A program for managing weight gain associated with atypical antipsychotics. Psychiatr Serv 2003;54:1155-7.
37. Menza M, Vreeland B, Minsky S, Gara M, Radler D, Sakowitz M. Managing atypical antipsychotic-associated weight gain: 12-month data on amultimodal weight control program. J Clin Psychiatry 2004;65:471-7.
38. Nemet D, Barkan S, Epstein Y, Friedland O, Kowen G, Eliakin A. Short-and long-term beneficial effects of a combined dietary-behavioral-physical activity intervention for the treatment of childhood obesity. Pediatrics 2005;115:443-9.
39. O'Keefe C, Noordsy D, Liss T, Weiss H. Reversal of antipsychotic- associated weight gain. J Clin Psychiatry 2003;64:907-12.
40. Weber M, Wyne K. A Cognitive/behavioral group intervention for weight loss in patients treated with atypical antipsychotics. Schizophr Res 2006;83:95-101.
41. Werneke U, Taylor D, Sanders T, Wessely S. Behavioral management of antipsychotic-induced weight gain: a review. Acta Psychiatr Scand 2003;108:252-9.
42. Faulkner G, Soundy A, Lloyd K. Schizophrenia and weight management: a systematic review of interventions to control weight. Acta Psychiatr Scand 2003;108:324-32.
43. Kalarchian M, Marcus M, Levine M, et al. Behavioral treatment of obesity in patients taking antipsychotic medications. J Clin Psychiatry 2005;66:1058-63.
44. Brar J, Ganguli R, Pandina G, Turkoz I, Berry S, Mahmoud R. Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 2005;66:205-12.
45. Braet C, Tanghe A, Decaluwe V, Moens E, Rosseel Y. Inpatient treatment for children with obesity: weight loss, psychological well-being, and eating behavior. J Pediatr Psychol 2004;29:519-29.
46. Carrell A, Clark R, Peterson S, Nemeth B, Sullivan J, Allen D. Improvement of fitness, body composition, and insulin sensitivity in overweight children in a school-based exercise program. Arch Pediatr Adolesc Med 2005;259:963-8.
47. Heilbronn L, Jonge L, Frisard M, et al. Effect of 6-month calorie restriction on biomarkers of longevity, metabolic adaptation, and oxidative stress in overweight individuals. J Am Med Assoc 2006;295:1539-47.
48. Cohen S, Glazewski R, Khan S, Khan A. Weight gain with risperidone among patients with mental retardation: effect of calorie restriction. J Clin Psychiatry 2001;62:114-6.
49. Saris W. Very-low-calorie diets and sustained weight loss. Obes Res 2001;9:295-301.
50. Yanovski J. Intensive therapies for pediatric obesity. Pediatr Clin North Am 2001;48:1041-53.
51. Simons-Morton D, Obarzanek E, Cutler J. Obesity research - limitations of methods, measurements, and medications. JAMA 2006;295:826-8.
52. Durant N, Cox J. Current treatment approaches to overweight in adolescents. Curr Opin Pediatr 2005;17:454-9.
53. Gupta S, Masand P, Virk S, et al. Weight decline in patients switching from olanzapine to quetiapine. Schizophr Res 2003;70:57-62.
54. Haan L, Amelsvoort T, Rosien K, Linszen D. Weight loss after switching from conventional olanzapine tablets to orally disintegrating olanzapine tablets. Psychopharmacology 2004;175:389-90.
55. Daniels S. Pharmacological treatment of obesity in pediatric patients. Pediatr Drugs 2001;3:405-10.
56. Molnar D. New drug policy in childhood obesity. Int J Obes 2005;29:562-5.
57. Henness S, Perry C. Orlistat: a review of its use in the management of obesity. Drugs 2006;66:1625-56.
58. Hanefeld M, Sachse G. The effects of orlistat on body weight and glycemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab 2002;4:415-23.
59. Muls E, Kolanowski J, Scheen A, Van Gaal L. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled multicenter study. Int J Obes 2001;25:1713-21.
60. Halpern A, Mancini M, Suplicy H, et al. Latin-American trial of orlistat for weight loss and improvement in glycemic profile in obese diabetic patients. Diabetes Obes Metab 2003;5:180-8.
61. Krempf M, Louvet J, Allanic H, Miloradovich T, Joubert J, Attall J. Weight reduction and long-term maintenance after 18-month treatment with orlistat for obesity. Int J Obes 2003;27:591-7.
62. Toplak H, Ziegler O, Keller U, et al. Weight reduction with orlistat in obese subjects receiving a mildly or moderately reducedenergy diet: early response to treatment predicts weight maintenance. Diabetes Obes Metab 2005;7:699-708.
63. Erdmann J, Lippl F, Klose G, Schusdziarra V. Cholesterol lowering effect of dietary weight loss and orlistat treatment - efficacy and limitations. Aliment Pharmacol Ther 2004;19:1173-9.
64. Chanoine J, Hampl S, Jensen C, Boldrin M, Hauptman J. Effect of orlistat on weight and body composition in obese adolescents. JAMA 2005;293:2873-934.
65. McDuffie J, Calis K, Uwaifo G, et al. Efficacy of orlistat as an adjunct to behavioral treatment in overweight African-American and Caucasian adolescents with obesity-related comorbid conditions. J Pediatr Endocrinol Metab 2004;17:307-19.
66. McDuffie J, Calis K, Uwaifo G, et al. Three-month tolerability of orlistat in adolescents with obesity-related comorbid conditions. Obes Res 2002;10:642-50.
67. Maahs D, de Serna D, Kolotkin R, et al. Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents. Endocr Pract 2006;12:18-28.
68. Poston W, Foreyt J. Sibutramine and the management of obesity. Expert Opin Pharmacother 2004;5:633-42.
69. Godoy-Matos A, Carraro L, Vieira A, et al. Treatment of obese adolescents with sibutramine: a randomized, double-blind, controlled study. J Clin Endocrinol Metab 2005;90:1460-5.
70. Garcia-Morales L, Berber A, Macias-Lara C, Lucio-Ortiz C, Del-Rio-Navaro BE, Dorantes-Alvarez LM. Use of sibutramine in obese Mexican adolescents: a month, randomized, double-blind, placebo-controlled parellel-group trial. Clin Ther 2006;28:770-82.
71. Violante-Ortiz R, Del-Rio-Navarro B, Lara-Esqueda A, et al. Use of sibutramine in obese Hispanic adolescents. Adv Ther 2005;22:642-9.
72. Berkowitz R, Wadden T, Tershakovee A, Cronquist J. Behavior therapy and sibutramine for the treatment of adolescent obesity. JAMA 2003;289:1805-12.
73. Dujovne C, Zavoral J, Rowe E, Mendel C. Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia. Am Heart J 2001;142:489-97.
74. Reisler G, Tauber T, Afriat R, Bortnik O, Goldman M. Sibutramine as an adjuvant therapy in adolescents suffering from morbid besity. Isr Med Assoc J 2006;8:30-2.
75. Fanghanel G, Cortinas L, Sanchez-Reyes L, Berber A. Second phase of a double-blind study clinical trial on sibutramine for the treatment of patients suffering essential obesity: 6months after treatment cross-over. Int J Obes 2001;25:741-7.
76. Henderson D, Copeland P, Daley T, Borba C, Cather C, Nguyen D. A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. Am J Psychiatry 2005;162:954-62.
77. Webb E, Viner R. Should metformin be prescribed to overweight adolescents in whom dietary/behavioural modifications have not helped? Arch Dis Child 2006;91:793-4.
78. Bridger T, MacDonald S, Baltzer F, Rodd C. Randomized placebo-controlled trial of metformin for adolescents with polycystic ovary syndrome. Arch Pediatr Adolesc Med 2006;160:241-6.
79. Glueck C, Aregawi D, Winiarska M, et al. Metformin-diet ameliorates coronary heart disease risk factors and facilitates resumption of regular menses in adolescents with polycystic ovary syndrome. J Pediatr Endocrinol Metab 2006;19:831-42.
80. Jones K, Arslanian S, Peterokova V, Park J, Tomlinson M. Effect of metformin in pediatric patients with type 2 diabetes. Diabetes Care 2002;25:89-94.
81. Paolisso G, Amato L, Eccellente R, et al. Effect of metformin on food intake in obese subjects. Eur J Clin Invest 1998;28:441-6.
82. Srinivasan S, Ambler G, Baur L, et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. J Clin Endocrinol Metab 2006;91:2074-80.
83. Kay J, Alemzadeh R, Langley G, D'Angelo L, Smith P, Holshouser S. Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism 2001;50:1457-61.
84. Freemark M, Bursey D. The effect of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics 2001;107:1-7.
85. Morrison J, Cottingham E, Barton B. Metformin for weight loss in pediatric patients taking psychotropic drugs. Am J Psychiatry 2002;159:655-7.
86. Klein D, Cottingham E, Sorter M, Barton B, Morrison J. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry 2006;163:2072-9.
87. Bray G, Hollander P, Klein S, et al. A 6 month randomized, placebo-controlled dose-ranging trial of topiramate for weight loss in obesity. Obes Res 2003 ;11:722-33.
88. Nickel M, Nickel C, Muehlbacher M, et al. Influence of topiramate on olanzapine-related adiposity in women. J Clin Psychopharmachol 2005;25:211-7.
89. Vieta E, Sanchez-Moreno J, Goikolea J, et al. Effects on weight and outcome of long-term olanzapine-topiramate combination treatment in bipolar disorder. J Clin Psychopharmacol 2004;24:374-8.
90. Lin Y, Liu C, Hsiao M. Management of atypical antipsychotic-induced weight gain in schizophrenic patients with topiramate. Psychiatry Clin Neurosci 2005;59:613-5.
91. Canitano R. Cllinical Experience with topiramate to counteract neuroleptic-induced weight gain in 10 individuals with autistic spectrum disorders. Brain Dev 2005;27:228-32.
92. Graham K, Gu H, Lieberman J, Harp J, Perkins D. Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with oanzapine. Am J Psychiatry 2005;162:1744-6.
93. Deberdt W, Winokur A, Cavazzoni P, et al. Amantadine for weight gain associated with olanzapine treatment. Eur Neuropsychopharmacol 2005;15:13-21.
94. Gracious B, Krysiak T, Youngstrom E. Amantadine treatment of psychotropic-induced weight gain in children and adolescents: case series. J Child Adolesc Psychopharmacol 2002;12:249-57.
95. Bahk W, Lee K, Chae J, Pae C, Jun T, Kim K. Open-label study of the effect of amantadine on weight gain induced by olanzapine. Psychiatry Clin Neurosci 2004;58:163-7.
96. Leibowitz S, Alexander J. Hypothalamic serotonin in control of eating behavior,meal size, and body weight. Biol Psychiatry 1998 ;44:851-64.
97. Henderson D, Louie P, Koul P, Maney L, Daley T, Nguyen D. Modafinil-associated weight loss in a clozapinetreated schizoaffective disorder patient. Ann Clin Psychiatry 2005;17:95-7.
98. Makris A, Rush C, Frederich R, Kelly T. Wake-promoting agents with different mechanisms of action: comparison of effects of modafinil and amphetamine on food intake and cardiovascular activity. Appetite 2004;42:185-95.
99. Greenhill L, Biederman J, Boellner S, et al. A randomized, double-blind, placebo-controlled study of modafinil filmcoated tablets in children and adolescents with attentiondeficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006;45:503-11.
100. Poyurovsky M, Pashinian A, Levi A, Weizman R, Weizman A. The effects of betahistine, a histamine H1 receptor agonist/ H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenic patients. Int Clin Psychopharmacol 2005;20:101-3.
101. Lopez-Mato A, Rovner J, Illa G, Vieitez A, Boullossa O. Randomized, open-label study on the use of ranitidine at different doses for the management of weight gain associated with olanzapine administration. Vertex 2003;14:85-96.
102. Ettinger M, Littlejohn T, Schwartz S, et al. Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults. JAMA 2003;289:1763-4
103. Norgren S, Danielsson P, Jurold R, Lotborn M, Marcus C. Orlistat treatment in obese prepubertal children: a pilot study. Acta Pediatr 2003;92:666-70.
104. Azar S, Zantout M. Diabetic ketoacidosis associated with orlistat treatment. Diabetes Care 2001;25:602.
105. Birkenfeld A, Schroeder C, Pischon T, et al. Paradoxical effect of sibutramine on autonomic cardiovascular regulation in obese hypertensive patients. Clin Auton Res 2005;15:200-6.
106. Jordan J, Scholze J, Matiba B, Wirth A, Hauner H, Sharma A. Influence of sibutramine on blood pressure: evidence from placebo-controlled trials. Int J Obes 2005;29:509-16.
107. Cordeiro , Vallada H. Sibutramine-induced mania episode in a bipolar patient. Int J Neuropsychopharmacol 2002;5:283-4.
108. Towbin K. Gaining: pediatric patients and use of atypical antipsychotics. Am J Psychiatry 2006;163:1034-6.
109. Lacher M, Hermanns-Clausen M, Haeffner K, Brandis M, Pohl M. Severe metformin intoxication with lactic acidosis in an adolescent. Eur J Pediatr 2005;164:362-5.
110. Aarsen F, van den Akker E. Effect of topiramate on cognition in obese children. Neurology 2006;1:1307-8.
111. Correll C, Carlson H. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolsec Psychiatry 2006;45:771-91.
112. Caprio S, Genel M. Confronting the epidemic of childhood obesity. JAMA 2004;292:2643-6.
113. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601.